Strides Pharma Science Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science, through its step-down subsidiary Strides Pharma International AG, has signed definitive agreements with Sandoz AG to acquire and in-license a portfolio of branded generic products across Sub-Saharan Africa, covering Western Sahara (10 countries), Ghana, Nigeria, and Kenya. The portfolio spans anti-infective, cardiovascular, and dermatology segments, with several brands individually generating over US$1 million in annual sales. The initial deal value is US$ 12 million, payable at closing and funded entirely through internal accruals, with no debt or equity dilution. The combined business is expected to make Strides one of the top five pharmaceutical players in SSA and among the top two in the representable market, more than doubling its regional presence. The transaction is expected to be EPS-accretive and close by end of Q2 FY27 (September 2026), subject to regulatory and antitrust approvals.
This is a value-accretive, cash-funded acquisition that significantly strengthens Strides' Africa franchise without straining the balance sheet, likely to be viewed positively by investors as it accelerates the company's 'in Africa for Africa' strategy and long-term growth ambitions in ex-US markets.